Introduction {#s1}
============

Coronary artery calcification score (CACS) is well validated prognostic tool in coronary artery disease (CAD). There is marked increased risk of cardiovascular event and death as the CACS increases in asymptotic patients \[[@R01]\]. Coronary artery calcification (CAC) is an early marker of atherosclerosis and usually precedes the development of CAD by many years \[[@R02]\]. CAC was first introduced into medicine as a screening test for the presence of atherosclerosis, based on studies that demonstrated the test is a specific albeit indirect, indicator for magnitude of underling atherosclerosis \[[@R03], [@R04]\]. Most frequently, the Agatston score has been used to measure the total coronary calcified plaques \[[@R05]\]. Absence of calcium in the coronary arteries does not mean absence of atherosclerosis, as there may be non-calcified plaques. However, this situation correlates to a disease of lower severity \[[@R06]\]. In a previous study, in the symptomatic patients, the absence of measurable CAC had a high negative predictive value of obstructive CAD \[[@R07]\], and may exclude inducible ischemia at functional testing as myocardial perfusion positron emission tomography (PET) in patients at low or intermediate risk for CAD \[[@R08]\]. However, there are some studies questioned the capability of CAC to rule out the obstructive CAD. In these studies, higher rates of obstructive noncalcified plaques (6% to 39%) or inducible ischemia (16%), especially in higher risk patients, unstable patients with unstable chest pain, and patients presented to the emergency department were found \[[@R9]-[@R12]\]. In general, the data on the prevalence of myocardial ischemia on single photon emission computed tomography (SPECT) in symptomatic patients with zero CACS and low to intermediate risk probability is lacking and controversial to some extent. Therefore, the aim of our study is to evaluate the capability of zero CACS to exclude myocardial ischemia on myocardial perfusion single photon emission computed tomography (MPS), and further to correlate between abnormal MPS and coronary computed tomography angiography (CCTA).

Materials and Methods {#s2}
=====================

Study population {#s2a}
----------------

From December 2011 to January 2016, a total of 157 patients (mean age: 53 ± 10 years, 88 (56%) female patients, 69 (44%) male patients) who were suspected to have CAD and having low to intermediate pretest likelihood for CAD according to Diamond and Forrester criteria \[[@R13]\], underwent CACS on dedicated CT scanners. CACS was reported as zero in all patients. Subsequently all patients underwent MPS, and was reported as normal, fixed defect, equivocal, and ischemic or reversible defect. Patients with abnormal MPS underwent additional imaging with CCTA. No further workup was performed for patients with normal MPS. The study was approved by the Institutional Review Committee of the hospital.

MPS acquisition and analysis {#s2b}
----------------------------

Patients underwent rest-stress myocardial perfusion studies with either a separate day protocol or a same day stress-rest sequence. The choice of tracer and same day or separate day protocol was based on logistic requirements. The rest dose in patients who underwent a separate day rest-stress protocol was 1,100 Megabecqurel (MBq) of either technetium-99 (Tc-99m) sestamibi or tetrofosmin. The stress dose in patients who underwent the rest-stress same day protocol was 1,100 MBq mCi of either (Tc99m) sestamibi or tetrofosmin. Tc-99m sestamibi or Tc-99m tetrofosmin was injected during peak pharmacological vasodilatation with adenosine (140 µg/kg/min), or dipyridamole. SPECT imaging was started 30 min following pharmacological vasodilatation. Rest SPECT myocardial perfusion imaging was initiated at approximately 60 min following injection. SPECT imaging was performed with line source attenuation correction at 90° dual-detector gamma camera (Cardio MD, Philips Medical System, Milpitas, California) equipped with attenuation correction and truncation compensation. The acquisition parameters and post processing were performed according to the most recent guidelines of the ASNC for nuclear cardiology procedures \[[@R14]\].

All images were reoriented in short, vertical, and horizontal views utilizing auto SPECT (Cedars-Sinai Medical Center, Los Angeles, California) for visual interpretation by an experienced nuclear medicine physician. The reader was not biased by clinical information. Stress and rest perfusion images were scored using 17 tomographic segments, which included six segments each for the basal and midventricular slices, and four segments for the apical short-axis slices. The final segment is located on the most apical part of the left ventricle. Finally, gated short-axis images were processed with quantitative SPECT software to measure the ejection fraction. In the visual analysis the 17 segments were scored for perfusion defects on a 4-point system (0 = normal; 1 = mild; 2 = moderate; and 3 = severe) for both the stress and rest images. From this analysis, ischemia was defined as a change in segmental score between stress and rest. Segments with no change between stress and rest were classified as nonreversible. Summed stress and rest scores were calculated by summing the 17 segmental scores in each imaged set. Utilizing the summed difference score (SDS) in measuring defect reversibility was calculated from the difference between the summed stress and rest scores. A SDS lower than 2 was considered nonischemic, 2 to 7 was considered as mild ischemia, and greater than 7 as considered as moderate to severe ischemia. The reader made the final determination of an abnormal SPECT study by comparing both the perfusion and functional data. The perfusion defects represented by the perfusion scores at stress and rest were used to form the interpretation of the MPS studies. A gated SPECT result was considered normal if as follows: no visual perfusion defect, summed stress score \< 3, a left ventricular ejection fraction (LVEF) at rest \> 50%.

Coronary artery calcium score acquisition and analysis {#s2c}
------------------------------------------------------

All patients with heart rates \> 70 bpm received oral β-blocker therapy, with 50 or 100 mg of metoprolol tartrate (AstraZeneca, Zoetermeer, the Netherlands) after stress testing to achieve a heart rate \< 70 bpm for the CAC scan. A non-enhanced CT scan (High Definition CT XT; GE Healthcare) during breath-hold at end expiration to calculate the total CAC score was acquired with ECG triggering at 75% of the R-R interval and with the following scanning parameters: 40 or 48 sections and 2.5-mm section thickness; gantry rotation time, 330 ms; tube voltage, 120 kV; and a tube current of 125 mA. If patients were not able to hold their breath, a free breathing CT was acquired. Post processing was conducted at a dedicated workstation using Smartscore software (GE Healthcare). The CAC score was calculated using the standard Agatston criteria \[[@R05]\].

Coronary CT angiography acquisition {#s2d}
-----------------------------------

Patients without contraindications received metoprolol targeting a heart rate of ≤ 65 bpm and nitroglycerin 0.8 mg sublingually before image acquisition. A bolus tracking technique was used to calculate the time interval between intravenous contrast (Visipaque 320, GE Healthcare, Milwaukee, Wisconsin, USA) infusion and image acquisition. Final images were acquired with a triphasic protocol (100% contrast, 40%/60% contrast/saline, and 40 mL saline). The contrast volume and infusion rate (5 to 6 mL/s) were individualized according to scan time and patient body habitus. Retrospective ECG-gated data sets were acquired with the GE high definition CT (GE Healthcare, Milwaukee, Wisconsin, USA) with 64 × 0.625 mm slice collimation and a gantry rotation of 350 ms (mA = 300 to 800, kV = 120). Pitch (0.16 to 0.24) was individualized to the patient's heart rate. The CCTA data sets were reconstructed with an increment of 0.4 mm using the cardiac phase with the least cardiac motion.

Coronary CT angiography image analysis {#s2e}
--------------------------------------

Images were processed using the GE Advantage Volume Share Workstation (GE Healthcare, Milwaukee, Wisconsin, USA) and visually interpreted by two expert observers blinded to all clinical data. A 17-segment model of the coronary arteries and 4-point grading score (normal, mild (\< 50%), moderate (50% to 69%), severe (≥ 70%)) was used for the evaluation of coronary stenosis. Obstructive CAD was defined as coronary diameter stenosis ≥ 50% \[[@R15]\].

Statistical analysis {#s2f}
--------------------

Data were entered into SPSS V 20.0 for analysis (SPSS, Chicago, Illinois). All continuous variables were expressed as mean ± standard deviation (SD). Relationship between categorical variables was assessed using Chi-square test. Comparison between groups was performed using two independent sample *t*-test. A P value of less than 0.05 indicated statistically significant difference.

Results {#s3}
=======

Our sample consisted of 157 patients, (mean age: 53 ± 10 years, 88 (56%) female patients, 69 (44%) male patients) who were suspected to have CAD and having low to intermediate pretest likelihood for CAD according to the Diamond and Forrester criteria ([Table 1](#T1){ref-type="table"}). All patients had zero CACS. A total of 122 (78%) patients had normal MPS, and 35 (22%) had abnormal MPS, abnormal MPS includes fixed defect 22(13%), equivocal 10 (6%), and reversible defect 4 (3%) ([Table 2](#T2){ref-type="table"}). All patients with abnormal MPS had further imaging with CTCA, CTCA was normal in 30 (85%) patients, one patient had coronary artery stenosis more than 50%, one patient had coronary artery stenosis less than 50%, one patient had anomalous origin coronary artery, and two patients had myocardial bridging ([Table 3](#T3){ref-type="table"}). There were several findings in patients with abnormal MPS and normal coronary artery such as dilated cardiomyopathy in 14 (40%) patients ([Fig. 1a, b](#F1){ref-type="fig"}), asymmetrical septal hypotrophy in one (3%) patient and mitral valve disease in three (9%) patients ([Table 4](#T4){ref-type="table"}). There was no association with conventional CAD risk factors with MPS results.

###### Baseline Demographics of The study Population

  --------------------------- -----------
  N                           157
  Age (years)                 53 ± 10
  Female                      88 (56%)
  Male                        69 (44%)
  Normal MPS                  122 (78%)
  Abnormal MPS                35 (22%)
  Diabetes mellitus           89 (57%)
  Hypertension                66 (66%)
  Smoking                     14 (9%)
  Hypercholesterolemia        33 (33%)
  Family history              6 (4%)
  Left ventricular function   60 ± 11%
  --------------------------- -----------

###### MPS Results

  ------------------- -----------
  N                   157
  Normal MPS          122 (78%)
  Abnormal MPS        35 (22%)
  Fixed defect        21 (13%)
  Equivocal           10 (6%)
  Reversible defect   4 (3%)
  ------------------- -----------

###### CT Coronary Angiography Results

  ---------------------------------- ----------
  N                                  35
  Normal coronary artery             30 (85%)
  Coronary artery stenosis           
    More than 50%                    1 (3%)
    Less than 50%                    1 (3%)
  Anomalous coronary artery origin   1 (3%)
  Myocardial bridging                2 (6%)
  ---------------------------------- ----------

![(a) A 42-year-old female with chest pain and shortness of breath. Myocardial perfusion scintigraphy demonstrates reversible defects in the apex and anterior wall (yellow arrows) and inferior wall (white arrows) suggesting inducible ischemia. Gated images (not shown) demonstrate mildly dilated left ventricular cavity and global hypokinesis and impaired left ventricle ejection fraction of 35%. SAX: short axis; VLA: vertical long axis; HLA: horizontal long axis. (b) Shaded surface display coronary computed tomography angiogram demonstrating normal coronary arteries without calcified or non-calcified plaques. A: ascending aorta; LM: left main; LAD: left anterior descending artery; D1: first diagonal artery; LCX: left circumflex artery; RCA: right coronary artery.](cr-09-028-g001){#F1}

###### CT Coronary Angiography and Cardiac Morphology Findings in Patients With Abnormal MPS

  --------------------------------------------------------------------- ----------
  N                                                                     35
  Normal CT coronary angiography and normal cardiac morphology          13 (37%)
  Abnormal CT coronary angiography and/or abnormal cardiac morphology   22 (63%)
  Dilated cardiomyopathy                                                14 (40%)
  Coronary artery stenosis, more than 50%                               1 (3%)
  Asymmetrical septal hypertrophy                                       1 (3%)
  Myocardial bridging                                                   2 (6%)
  Anomalous coronary artery origin                                      1 (3%)
  Mitral valve disease (stenosis, post mitral valve replacement)        3 (9%)
  --------------------------------------------------------------------- ----------

Discussion {#s4}
==========

Our data show that a CAC score of zero has less than 1% (0.6%) flow limiting CAD based on CCTA in symptomatic stable patients with low to intermediate probability of CAD. It appears that CAC score in this group of patients is appropriate, safe, and cost-effective as initial diagnostic test for CAD. However, the prevalence of abnormal MPS in patients with CAC score of zero is relatively high up to 22%. Most patients with abnormal MPS do not have obstructive CAD. Based in our data, one patient out of 35 patients with abnormal MPS had obstructive CAD based on CCTA. Importantly, CCTA showed other findings that potentially explaining the abnormal perfusion on myocardial imaging such as dilated and hypertrophic cardiomyopathy, mitral valve disease, and myocardial bridging. This finding is extremely important indicating that not all abnormal myocardial perfusion in absence of obstructive CAD based on conventional coronary angiography is false positive.

According to our data, it is appropriate to initiate the cardiac workup for patients with low to intermediate risk with CAC score due to its relatively low cost, low radiation, and wide availability. Further functional imaging with MPS is indicated to exclude myocardial ischemia. In patients with zero CAC score and normal MPS no further workup is indicated, however, with abnormal MPS additional imaging with CCTA may be indicated.

Prevalence of obstructive CAD among patients with a zero CAC score {#s4a}
------------------------------------------------------------------

The prevalence of obstructive CAD in patients with zero CAC is variable from less than 1% to about 3% based strongly on population studied, patient's presentation, and pretest probability of CAD. In asymptomatic patients with a zero CAC score, the prevalence of obstructive CAD is lower than 1% \[[@R16]\]. However, in symptomatic patients, a zero CAC score is associated with a low likelihood of up to 3%. In a systematic review by Sarawar et al, it has been shown that absence of CAC was associated with a very low risk of further cardiovascular event; with a modest incremental value of other diagnostic test in this this very low risk group \[[@R17]\]. In another major study by Villines et al, 10,037 symptomatic patients without CAD who underwent CCTA and CAC scoring, of which 84% had no CAD, 13% had no obstructive CAD, and 3.5% had more than 50% stenosis. It was concluded that in symptomatic patients with a zero CAC score, obstructive CAD is possible and is associated with increased cardiovascular events, and CAC score did not add incremental prognostic information to CCTA \[[@R07]\].

Relationship between zero CAC score and myocardial perfusion {#s4b}
------------------------------------------------------------

In our study, 35 (22%) patients out of 157 patients with zero CAC score have abnormal myocardial perfusion (abnormal MPS). The pattern of perfusion abnormalities includes fixed defect 21 (13%), equivocal myocardial perfusion10 (6%), and reversible defect 4 (3%), but obstructive CAD is identified in one patient only based on CCTA. Interestingly, there are many cardiac morphological abnormalities on CCTA that could potentially explain the abnormal myocardial perfusion in absence of obstructive CAD. For example, CCTA shows one patient with anomalous origin right coronary artery from left coronary ostia, two patients with myocardial bridging, and one patient with non-obstructive CAD (less than 50% luminal stenosis). All these patients have zero CAC score, abnormal myocardial perfusion, and patent coronary arteries. This finding could explain patients' symptoms and abnormal myocardial perfusion and not necessarily indicate false positive MPS. In addition, there are several cardiac morphological abnormalities on CCTA, such as dilated cardiomyopathy (DCMP), hypertrophic cardiomyopathy (HCMP), and mitral valve disease. Previous study showed that, SPECT perfusion abnormalities in patients with normal coronary artery on CCTA was 12% \[[@R18]\] which is relatively less than our population. We strongly believe these important findings and may explain why in many previous studies that MPS had low specificity when compared to gold standard conventional coronary angiography. For example, in our patients, there are 14 patients out of 35 have DCMP, one patient has HCMP, and two patients has mitral valve disease. There are several possible reasons for the presence of perfusion defect in DCMP. The presence of myocardial fibrosis and scarring could account for fixed perfusion defect \[[@R19]\]. In addition, dilatation of left ventricle and abnormal cell membrane could cause variable tracer uptake and distribution. It was also known that stress-induced left ventricle geometric change may cause reversible perfusion defects in DCMP. Exercise-induced coronary spasm, mitral valve prolapse, and aortic valve stenosis had been associated with myocardial perfusion abnormalities \[[@R20]\]. In hypertrophic cardiomyopathy, there is thickening of the myocardium, practically the septum; this can result in significant increased activity in the septum, which results in the significant deceased uptake in the other myocardial walls creating perfusion abnormalities \[[@R21]\].

The negative predictive value of zero CAC versus exercise testing and myocardial perfusion imaging {#s4c}
--------------------------------------------------------------------------------------------------

Dedic et al, in a study consistent of 791 consecutive stable patients showed that patients with stable chest pain who underwent CAC scoring and exercise electrocardiogram, a zero CAC score had substantial lower likelihood ratio compared to the exercise electrocardiogram; 0.11, 0.13, 0.13 vs. 0.93, 0.55, 0.46 in the low, intermediate, and high risk group. In low risk patients (0-30%) a negative CAC reduced the likelihood of obstructive CAD to 5% obviating the need for further diagnostic workup in substantial proportion of patients. For intermediate risk patients (30-70%) the likelihood decreased to 5-25%, but in high risk group zero CAC score cannot exclude obstructive CAD \[[@R22]\]. The negative predictive value of zero CAC score for detection of myocardial ischemia was investigated by Esteves et al. A total of 99 patients out of 206 patients had zero CACS, and of those 99 patients only one patient had myocardial ischemia on myocardial perfusion PET, also CACS of zero was the strongest independent factors of normal myocardial perfusion PET \[[@R08]\]. Despite this high negative predictive value of zero CACS for prediction of myocardial ischemia, we strongly believe, further testing with MPS or CCTA is necessarily in patients with zero CACS presented to the emergency department, patients with higher pretest probability, and young patients with high suspicious of coronary artery anomalies. CCTA is particularly helpful in patients with high suspicious of false positive MPS such as patients with DCMP, HCMP, left bundle branch block, coronary artery anomalous, and patients with known structural or congenital heart disease.

Study limitations {#s4d}
-----------------

One of our study limitations is that our gold standard for evaluating CAD was CCTA instead of invasive coronary angiography, which is the gold standard method of detection of CAD, However, many studies have shown that CCTA has 90-94% sensitivity and 96-100% negative predictive value \[[@R23]\].Our patients with normal MPS did not undergo any further imaging, potential false negative could not be completely excluded due to many reasons such as balanced ischemia and or left main coronary artery disease. Also this group of patients with normal SPECT may have noncalcified plaque or non-obstructive CAD.

Conclusions {#s4e}
-----------

In conclusion, zero CACS in stable patients with low or intermediate risk indicates very low likelihood of obstructive CAD, less than 1% and normal MPS most likely will not benefit from further testing. However, patients with abnormal MPS will need further imaging with CCTA. CCTA is particular helpful in this group of patients for not only for evaluation of coronary artery disease but also for cardiac morphological evaluation.
